In 2018, Domain Therapeutics and Boehringer Ingelheim (Ingelheim am Rhein, Germany) entered into a multi-target collaboration and licensing agreement to address orphan GPCR for neuropsychiatric disorders and potential other indications.
Domain Therapeutics will bring its proprietary platforms and expertise in GPCR medicinal chemistry and pharmacology to design, optimize and identify candidates on challenging targets. Boehringer Ingelheim will support research activities and will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration. Under the terms of the agreement, Domain will be eligible for undisclosed upfront, success-based milestones on the research, development milestones and royalties (see press release).
In 2019, Domain announced the achievement of key discovery milestones in two independent projects (see press release).